RECRUITING Not applicable ClinicalTrials.gov

Contribution of Multicenter Expertise and Deformable Fusion Software for Re-irradiations With Curative Intent

Sponsor: Centre Leon Berard • ClinicalTrials.gov ID: NCT06668038

Registry updated: 2026-09-15

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

We propose to evaluate the contribution of a standardized process combining, * a validation of re-irradiation indications by a group of multi-professional experts (radiotherapists and physicists) and, * a collective validation of the accumulation of doses on all the organs of the anatomical region concerned obtained using deformable fusion software (MiM) allowing the accumulation of doses in terms of Equivalent Dose 2 Grays (EQD2). The primary objective of this study is to determine the rate of patients for whom this process has changed the treatment plan.

Interventions

Multidisciplinary and multicenter validation of re-irradiation with curative intent (Other)
Validation in multidisciplinary and multicenter meeting of re-irradiation indication after review of technical data (images, structures and doses) of 1st irradiation and recent diagnosis images of the lesion to be irradiated, merged using MIM. In case of re-irradiation validation, validation in multidisciplinary and multicenter meeting of cumulated doses after review of EQD2 doses summation using MIM.

Eligibility criteria

Inclusion Criteria: * Age ≥ 18 years when signing the consent form * Re-irradiation with desired curative intent (≥ 50 Gy EQD2), with volume to be irradiated totally or partially included in a previous irradiation field: * Oligo-metastases or oligo-progression (\< 5 metastases in less than 3 sites) * Second cancer * Isolated local recurrence * Life expectancy \> 6 months * Dated and signed informed consent * Affiliation to a social security scheme or equivalent Exclusion Criteria: * Indication of intracranial, prostate, rectum or esophagus re-irradiation * Diagnosis of multi-metastatic cancer * PS ECOG ≥ 2 * Impossibility to interrupt current treatment with a tyrosine kinase inhibitor or other systemic treatment (excluding hormonal therapy) which may potentiate the rays effects (duration of wash-out according to treatment instructions) * Pregnant or breastfeeding women * Tutorship or curatorship or deprivation of liberty

Conditions

Re-irradiation Radiotherapy

Locations

Institut de Cancerologie de L'Ouest — Angers, France
Ch Bourg En Bresse — Bourg-en-Bresse, France
Centre Georges Francois Leclerc — Dijon, France
Chu Grenoble Alpes — Grenoble, France
Centre Leon Berard — Lyon, France
Aphp Marseille Chu Timone Et Hopital Nord Marseille — Marseille, France
Centre Antoine Lacassagne — Nice, France
Institut de Cancerologie de L'Ouest — Saint-Herblain, France
Centre Marie Curie — Valence, France
Centre de Radiotherapie Du Beaujolais — Villefranche-sur-Saône, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment